Alphamab Oncology Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
515
- Stock Symbol
-
09966
- Investments
-
3
- Share Price
-
$0.65
- (As of Friday Closing)
Alphamab Oncology General Information
Description
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
Contact Information
Website
www.alphamabonc.comCorporate Office
- 218 XingHu Street
- Suzhou Industrial Park, Bldg. C23
- Suzhou, Jiangsu 215125
- China
Corporate Office
- 218 XingHu Street
- Suzhou Industrial Park, Bldg. C23
- Suzhou, Jiangsu 215125
- China
Alphamab Oncology Stock Performance
As of 20-Nov-2026, Alphamab Oncology’s stock price is $0.65. Its current market cap is $628M with 964M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.65 | $0.68 | $0.64 - $1.56 | $628M | 964M | 1.18M | -$0.03 |
Alphamab Oncology Financials Summary
As of 30-Jun-2026, Alphamab Oncology has a trailing 12-month revenue of $74M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 684,514 | 1,030,095 | 276,883 | 640,543 |
| Revenue | 74,033 | 78,739 | 89,204 | 30,923 |
| EBITDA | (18,844) | (10,722) | 28,436 | (28,741) |
| Net Income | (25,149) | (15,844) | 23,182 | (29,766) |
| Total Assets | 318,554 | 299,722 | 307,086 | 301,486 |
| Total Debt | 39,505 | 17,577 | 25,474 | 36,267 |
Alphamab Oncology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Alphamab Oncology Comparisons
Industry
Financing
Details
Alphamab Oncology Competitors (59)
One of Alphamab Oncology’s 59 competitors is Abbisko Medicine, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abbisko Medicine | Formerly VC-backed | Shanghai, China | ||||
| GT Biopharma | Corporation | San Francisco, CA | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| EMD Serono | Corporation | Boston, MA | ||||
| Decode Genetics | Formerly VC-backed | Reykjavik, Iceland |
Alphamab Oncology Signals
Alphamab Oncology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Alphamab Oncology Investments (3)
Alphamab Oncology’s most recent deal was a Secondary Transaction - Private with Panomix. The deal was made on 19-Apr-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Panomix | 19-Apr-2019 | Secondary Transaction - Private | Laboratory Services (Healthcare) | ||
| SmartNuclide | 21-Mar-2016 | Seed Round | Drug Discovery | ||
| Panomix | 01-Jan-2016 | Early Stage VC | Laboratory Services (Healthcare) |
Alphamab Oncology ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Alphamab Oncology FAQs
-
When was Alphamab Oncology founded?
Alphamab Oncology was founded in 2008.
-
Where is Alphamab Oncology headquartered?
Alphamab Oncology is headquartered in Suzhou, China.
-
What is the size of Alphamab Oncology?
Alphamab Oncology has 515 total employees.
-
What industry is Alphamab Oncology in?
Alphamab Oncology’s primary industry is Pharmaceuticals.
-
Is Alphamab Oncology a private or public company?
Alphamab Oncology is a Public company.
-
What is Alphamab Oncology’s stock symbol?
The ticker symbol for Alphamab Oncology is 09966.
-
What is the current stock price of Alphamab Oncology?
As of 20-Nov-2026 the stock price of Alphamab Oncology is $0.65.
-
What is the current market cap of Alphamab Oncology?
The current market capitalization of Alphamab Oncology is $628M.
-
What is Alphamab Oncology’s current revenue?
The trailing twelve month revenue for Alphamab Oncology is $74M.
-
Who are Alphamab Oncology’s competitors?
Abbisko Medicine, GT Biopharma, BeOne Medicines, EMD Serono, and Decode Genetics are some of the 59 competitors of Alphamab Oncology.
-
What is Alphamab Oncology’s annual earnings per share (EPS)?
Alphamab Oncology’s EPS for 12 months was -$0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process